A Phase 3 interventional study of riboflavin solution and placebo solution in Keratoconus, sponsored by Glaukos Corporation. Completed at 8 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-04-26.
Sponsored by Glaukos Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing riboflavin in Keratoconus — 5 open to participants now, 8 under way, 7 of them phase 3. Riboflavin · Keratoconus.
Among the 23 studies testing riboflavin in Keratoconus, this one is the 11th largest by enrollment, is one of 3 that started in 2012, is one of 12 in phase 3, and was the 11th registered.
313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.
Browse Keratoconus studies →5 of the 23 studies testing riboflavin in Keratoconus are open now, in 1 country. Recruiting first, the newest first:
Price Vision Group · Sites in United States
Ages 10–90
Cornea and Laser Eye Institute · Sites in United States
Ages 18+ · Healthy volunteers
Cornea and Laser Eye Institute · Sites in United States
Ages 12+ · Healthy volunteers
Cornea and Laser Eye Institute · Sites in United States
Ages 12+ · Healthy volunteers
Kent Wellish MD
Ages 12+
By country, each count listing its studies:
Riboflavin: first FDA approval 1953 (M.V.I.-12 ADULT). What it is approved for, and how studies give it, is on its page →
Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 16 · Phase 4 1
First in 2008; this study’s year is marked. 3 started in 2012.
This study's enrollment of 230 is above the median of 40 across 205 interventional studies indexed under Keratoconus.
Median enrollment 170 across the 23 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
Glaukos Corporation has 9 studies filed under Keratoconus — fewer than ten, so there is no comparison to draw.
1 of the studies testing riboflavin in Keratoconus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04731727Kent Wellish MDTreating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing riboflavin in Keratoconus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression of, and/or reducing, maximum corneal curvature.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet all of the following criteria in order to be enrolled into the trial:
Having topographic evidence of keratoconus with a diagnosis of mild, moderate, or severe keratoconus defined as the following:
Mild Keratoconus:
Moderate Keratoconus:
Severe Keratoconus:
Exclusion Criteria:
Patients must not meet any of the following criteria in order to be enrolled in the trial:
Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications. For example:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by UVA irradiation for 4 minutes
Drug: riboflavin solution · Device: KXL System
Subjects will receive 0.0% riboflavin ophthalmic solution (Placebo) followed by UVA Irradiation for 4 minutes
Drug: placebo solution · Device: KXL System
0.12% riboflavin ophthalmic solution
Also known as: VibeX
0.0% riboflavin ophthalmic solution
Also known as: placebo
30 mW/cm2
Also known as: UVA Irradiation
Mean change in maximum corneal curvature (Kmax) between the VibeX active treatment group and placebo control group
Time frame: baseline to 6 months
Mean change in maximum corneal curvature (Kmax) between the VibeX active treatment group and placebo control group
Time frame: baseline to 12 months
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jul 2012, a primary completion of Jul 2015 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Riboflavin